Multiple Endocrine Neoplasia Type 1
"Multiple Endocrine Neoplasia Type 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of multiple endocrine neoplasia that is characterized by the combined occurrence of tumors in the PARATHYROID GLANDS, the PITUITARY GLAND, and the PANCREATIC ISLETS. The resulting clinical signs include HYPERPARATHYROIDISM; HYPERCALCEMIA; HYPERPROLACTINEMIA; CUSHING DISEASE; GASTRINOMA; and ZOLLINGER-ELLISON SYNDROME. This disease is due to loss-of-function of the MEN1 gene, a tumor suppressor gene (GENES, TUMOR SUPPRESSOR) on CHROMOSOME 11 (Locus: 11q13).
| Descriptor ID |
D018761
|
| MeSH Number(s) |
C04.588.322.400.500 C04.651.600.500 C04.700.630.500 C16.320.700.630.500 C19.344.400.500
|
| Concept/Terms |
Multiple Endocrine Neoplasia Type 1- Multiple Endocrine Neoplasia Type 1
- Multiple Endocrine Neoplasia Type I
- Neoplasms, Multiple Endocrine Type I
- Multiple Endocrine Neoplasms Type 1
- Neoplasia, Multiple Endocrine Type 1
- Neoplasms, Multiple Endocrine Type 1
- Wermer Syndrome
|
Below are MeSH descriptors whose meaning is more general than "Multiple Endocrine Neoplasia Type 1".
Below are MeSH descriptors whose meaning is more specific than "Multiple Endocrine Neoplasia Type 1".
This graph shows the total number of publications written about "Multiple Endocrine Neoplasia Type 1" by people in this website by year, and whether "Multiple Endocrine Neoplasia Type 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 |
| 2017 | 2 | 0 | 2 |
| 2018 | 3 | 0 | 3 |
| 2019 | 2 | 0 | 2 |
| 2020 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Multiple Endocrine Neoplasia Type 1" by people in Profiles.
-
Metastatic Potential and Survival of Duodenal and Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1: A GTE and AFCE Cohort Study (Groupe d'étude des Tumeurs Endocrines and Association Francophone de Chirurgie Endocrinienne). Ann Surg. 2020 12; 272(6):1094-1101.
-
Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters. J Clin Endocrinol Metab. 2020 01 01; 105(1).
-
68Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1. J Clin Endocrinol Metab. 2019 12 01; 104(12):5843-5852.
-
One-Year Postoperative Mortality in MEN1 Patients Operated on Gastric and Duodenopancreatic Neuroendocrine Tumors: An AFCE and GTE Cohort Study. World J Surg. 2019 11; 43(11):2856-2864.
-
Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small =2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study: Association Francophone de Chirurgie Endocrinienne & Groupe d'Etude des Tumeurs Endocrines. Ann Surg. 2018 07; 268(1):158-164.
-
Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database. Endocrine. 2018 10; 62(1):215-233.
-
Histologically Proven Bronchial Neuroendocrine Tumors in MEN1: A GTE 51-Case Cohort Study. World J Surg. 2018 01; 42(1):143-152.
-
Foxa2, a novel protein partner of the tumour suppressor menin, is deregulated in mouse and human MEN1 glucagonomas. J Pathol. 2017 05; 242(1):90-101.
-
Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. Endocrine. 2017 Nov; 58(2):349-359.
-
Insulinoma of genetic aetiology. Ann Endocrinol (Paris). 2013 Jul; 74(3):200-2.